Latest news

Featured in CLI 01.09.2022: Secretoneurin: the next biomarker for cardiovascular disease.

Secretoneurin is a small neuropeptide detectable in the blood and is strong predictor for mortality in several patient cohorts with underlying cardiovascular disease. Here CardiNor introduce themselves and their work to develop a secretoneurin test to use as part of a biomarker panel for cardiovascular disease.

Secretoneurin: the next biomarker for cardiovascular disease – Clinical Laboratory int. (clinlabint.com)

Data from the GISSI Heart Failure study where 1273 patients followed for more than 6 years had their Secretoneurin measured, is presented as Moderated ePosters at the ESC Congress in Barcelona August 28th, station 3 at 14:15 by Dr. Helge Røsjø MD, PhD (Akershus University Hospital, Norway): Circulating Secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure.

Dag Christiansen, CardiNor AS, will be present at the ePosters presentation and is available for questions.

In the media

Clinical Laboratory International, 01.09.2022:

Secretoneurin: the next biomarker for cardiovascular disease – Clinical Laboratory int. (clinlabint.com)

Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)

Secretoneurin forutsier død ved akutt respirasjonssvikt

Scientific Nordic, 02.10.2015:

Peptide found that predicts heart failure

Unicard, 12.03.2015:

Blodprøve kan fange opp risikopasienter ved hjertesvikt

VG, 27.09.2015:

Dette stoffet kan forutsi hjertedød.

Events

Poster accepted for presentation at European Society of Cardiology annual meeting in Munich on 28th of august. Low concentrations of circulating secretoneurin predict a favourable prognosis after cardiac surgery

Contact Us

Send us an email and we'll get back to you, asap.